Rege Nephro Co., Ltd. is a company that researches and develops various solutions against kidney diseases, improves the quality of life among patients suffering from kidney diseases, and contributes to society.

Rege Nephro Co., Ltd.

Rege Nephro is a clinical-stage biotech company developing cell therapy for chronic kidney disease (CKD) and small molecule for autosomal dominant polycystic kidney disease (ADPKD), and founded in 2019.
There are 13 million patients with CKD in Japan, of which 340,000 are severe CKD patients forced to undergo artificial dialysis. The healthcare cost of dialysis is $12 billion, 4% of the total healthcare cost of Japan.
However, there is still no curative treatment for CKD. Rege Nephro tries to treat patients suffering from CKD with cell therapy using nephron progenitor cells differentiated from iPS cells.

Fujifilm

JAFCO

Japan Science and Technology Agency

Kyogin Lease & Capital

Kyoto University Innovation Capital

Healthcare Innovation

We are pleased to announce the signing of a licensing agreement for non-exclusive implementation of patents related to C4U and CRISPR-Cas3 technologies. This agreement allows us to move forward with our innovations and developments. We look forward to further advancements and collaborations in the future!
https://lnkd.in/gQVigBEt

JP:CO:REGENEPHRO

Rege Nephro Co., Ltd.

locale

market

industry

website

crunchbase

linkedin

peer of

Metrics